Atara Biotherapeutics (ATRA) Income from Continuing Operations (2013 - 2026)
Atara Biotherapeutics (ATRA) reported Income from Continuing Operations of 4145000.0 for Q1 2026, down 110.91% on a YoY basis from 38010000.0 in Q1 2025, and up 88.53% quarter-over-quarter from 36143000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Atara Biotherapeutics has reported Income from Continuing Operations for 14 years, with the latest figure at 4145000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 110.91% year-over-year to 4145000.0; the trailing twelve-month figure through Mar 2026 stood at 42204000.0 (down 169.83% YoY), and the FY2025 full-year result was 49000.0, up 99.94% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 4145000.0, up from 36143000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 38010000.0 in Q1 2025, with the low at 88105000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 34963470.59 across 5 years, with a median of 31752000.0 in 2024.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations tumbled 485.08% — and 2025, when it jumped 219.71%.
- Atara Biotherapeutics' Income from Continuing Operations stood at 74677000.0 in 2022, then increased by 18.72% to 60699000.0 in 2023, then soared by 79.09% to 12693000.0 in 2024, then slumped by 184.75% to 36143000.0 in 2025, then jumped by 88.53% to 4145000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 4145000.0 (Q1 2026), 36143000.0 (Q4 2025), and 4303000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Atara Biotherapeutics | 137.85 Mn | 129.45 Mn | 392,000.00 | -4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.15 Mn |
| Dec 31, 2025 | -36.14 Mn |
| Sep 30, 2025 | -4.30 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 38.01 Mn |
| Dec 31, 2024 | -12.69 Mn |
| Sep 30, 2024 | -21.91 Mn |
| Jun 30, 2024 | -19.05 Mn |
| Mar 31, 2024 | -31.75 Mn |
| Dec 31, 2023 | -60.70 Mn |
| Sep 30, 2023 | -69.80 Mn |
| Jun 30, 2023 | -71.11 Mn |
| Mar 31, 2023 | -74.77 Mn |
| Dec 31, 2022 | -74.68 Mn |
| Sep 30, 2022 | -84.09 Mn |
| Jun 30, 2022 | 18.47 Mn |
| Mar 31, 2022 | -88.11 Mn |
| Dec 31, 2021 | -93.35 Mn |
| Sep 30, 2021 | -84.66 Mn |
| Jun 30, 2021 | -83.79 Mn |